Pirtobrutinib + Mosunetuzumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Grade 1 Follicular Lymphoma
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Trial Timeline
Nov 17, 2025 → Jul 31, 2031
NCT ID
NCT06948786About Pirtobrutinib + Mosunetuzumab
Pirtobrutinib + Mosunetuzumab is a phase 2 stage product being developed by Eli Lilly for Grade 1 Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06948786. Target conditions include Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06948786 | Phase 2 | Recruiting |
Competing Products
20 competing products in Grade 1 Follicular Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-α-NET | Perspective Therapeutics | Phase 1 | 25 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 52 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Letrozole | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 52 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 52 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Cilengitide | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Human Papillomavirus vaccine | Merck | Phase 2 | 52 |